Neoneuron

Executive Summary

Neoneuron is a private, Boston-based cell therapy company founded in 2018 with a vision to develop regenerative treatments for Parkinson’s disease and other neurodegenerative conditions. The company focuses on advancing cell-based therapies through scientific innovation and strategic partnerships, aiming to provide viable treatment options for patients worldwide. While still in early stages, Neoneuron’s patient-centered approach and focus on a high-unmet-need area position it within the competitive cell and gene therapy landscape. As a preclinical-stage entity, its progress hinges on successful research and development, regulatory milestones, and securing funding to advance its pipeline.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Parkinson’s Disease Candidate30% success
• Q3 2026Series A Financing or Grant Award50% success
• Q2 2026Preclinical Data Presentation at Major Conference40% success